Reading FDA Orange Book Therapeutic Equivalence Codes

The FDA Orange Book can help a pharmacy understand whether certain multisource prescription products have an FDA therapeutic-equivalence evaluation. Its two-letter codes are easy to oversimplify. “A means generic, B means brand” is wrong, and the code does not itself authorize every substitution in every state. The first letter communicates FDA’s equivalence category; the second adds information about the type of evaluation or product.

What the Orange Book lists

The publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, identifies drug products approved by FDA on the basis of safety and effectiveness and includes patent and exclusivity information. The product table groups products by active ingredient, dosage form, and route, with strength and therapeutic-equivalence information. Products may also be identified as reference listed drugs or reference standards.

A technician may encounter Orange Book concepts when comparing a generic product, helping locate product information, or studying generic substitution. The Orange Book is a technical reference. It is not a patient-specific recommendation, and a technician should not use it to independently change a prescription or promise that a particular product may be substituted. State pharmacy law and the pharmacist’s review govern the actual dispensing decision.

Read the first letter correctly

FDA’s preface describes two broad categories. Products with an “A” code are considered therapeutically equivalent to other pharmaceutically equivalent products under FDA’s evaluation. The products generally have no known or suspected bioequivalence problem, or an identified problem has been resolved with adequate evidence. Products with a “B” code are not currently considered therapeutically equivalent to those products because a bioequivalence issue has not been resolved, quality information is inadequate, or FDA has an insufficient basis to make the equivalence determination.

“B” does not mean unsafe or unapproved. It means FDA has not determined therapeutic equivalence to the relevant product under the Orange Book’s criteria. “A” also does not mean that every product with the same ingredient is interchangeable with every other dosage form or strength. The products must be pharmaceutically equivalent and grouped appropriately for the evaluation.

The second letter adds context

The second character identifies more detail about dosage form, route, or the nature of the evaluation. AB is a common code for products that meet bioequivalence requirements. Other A codes include AA, AN, AO, AP, and AT, depending on the product category. B codes include several subtypes such as BX, which indicates that FDA has insufficient information to determine therapeutic equivalence. The code should be read using the current Orange Book preface, not memorized from a single example.

Some codes include a number, such as AB1 or AB2, when there are multiple reference listed drugs under the same heading. The number identifies which reference product the generic was compared against. This matters because two extended-release products with the same active ingredient and strength may not necessarily be bioequivalent to each other unless the data support that relationship.

Therapeutic equivalence is not the same as generic status

A generic drug is approved by FDA under an abbreviated new drug application and must meet applicable standards. Therapeutic-equivalence evaluations are a separate listing that can help indicate whether products are expected to have the same clinical effect and safety profile when used under the labeled conditions. Not every generic or multisource product will have a simple AB code, and a code can change as FDA receives new data or reviews a product. Check the current edition or electronic database when accuracy matters.

State substitution laws still apply

FDA’s equivalence code is not the entire legal rule for substitution at the pharmacy counter. States have laws and regulations that determine whether substitution is required, permitted, prohibited, or subject to patient or prescriber instructions. The pharmacist evaluates the prescription, product, and state law. A pharmacy technician may retrieve the product information or flag a mismatch but must refer a substitution question to the pharmacist.

A practical lookup sequence

1. Search the active ingredient in the current FDA Orange Book.
2. Match the dosage form and route; do not compare unlike products.
3. Compare the strength and product grouping.
4. Read the complete TE code and consult the current preface for its meaning.
5. Check reference listed drug and reference standard identifiers where relevant.
6. Apply the state substitution rule and the pharmacist’s direction before any product change.

Worked example: two extended-release products

A technician sees two products with the same active ingredient and a similar-looking name, but one is an extended-release tablet. The technician should not assume that the products are interchangeable based on ingredient alone. The pharmacist checks the precise dosage form, strength, Orange Book grouping, TE code, prescription instructions, and applicable state law. If the products do not share the appropriate equivalence relationship, the pharmacist contacts the prescriber or follows the state’s required process.

Exam takeaway

The Orange Book’s first TE-code letter places products in FDA’s broad A or B equivalence category; the second letter and any number add detail. Match ingredient, dosage form, route, and strength, read the current preface, and remember that state law and pharmacist judgment govern actual substitution.